-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Analyzing Valneva (NASDAQ:VALN) & Titan Pharmaceuticals (NASDAQ:TTNP)
Analyzing Valneva (NASDAQ:VALN) & Titan Pharmaceuticals (NASDAQ:TTNP)
Valneva (NASDAQ:VALN – Get Rating) and Titan Pharmaceuticals (NASDAQ:TTNP – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.
Earnings & Valuation
This table compares Valneva and Titan Pharmaceuticals' top-line revenue, earnings per share and valuation.
Get Valneva alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Valneva | $411.85 million | 2.52 | -$86.87 million | N/A | N/A |
Titan Pharmaceuticals | $1.53 million | 9.36 | -$8.78 million | N/A | N/A |
Titan Pharmaceuticals has lower revenue, but higher earnings than Valneva.
Institutional & Insider Ownership
15.8% of Valneva shares are owned by institutional investors. Comparatively, 32.5% of Titan Pharmaceuticals shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 2.7% of Titan Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.Profitability
This table compares Valneva and Titan Pharmaceuticals' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Valneva | N/A | N/A | N/A |
Titan Pharmaceuticals | -1,779.72% | -183.12% | -123.74% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Valneva and Titan Pharmaceuticals, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Valneva | 0 | 2 | 1 | 0 | 2.33 |
Titan Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
Valneva currently has a consensus price target of $25.00, indicating a potential upside of 66.89%. Given Valneva's stronger consensus rating and higher probable upside, research analysts clearly believe Valneva is more favorable than Titan Pharmaceuticals.
Volatility & Risk
Valneva has a beta of 2.84, meaning that its share price is 184% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
Summary
Valneva beats Titan Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
About Valneva
(Get Rating)
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
About Titan Pharmaceuticals
(Get Rating)
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
Valneva (NASDAQ:VALN – Get Rating) and Titan Pharmaceuticals (NASDAQ:TTNP – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.
瓦尔内瓦(纳斯达克:VALN-GET评级)和泰坦制药(纳斯达克:TTNP-GET评级)都是小盘医疗公司,但哪一家是优势投资?我们将根据这两家公司的股息、风险、收益、机构所有权、盈利能力、估值和分析师建议的强弱对它们进行比较。
Earnings & Valuation
收益与估值
This table compares Valneva and Titan Pharmaceuticals' top-line revenue, earnings per share and valuation.
该表格比较了Valneva和Titan PharmPharmticals的营收、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Valneva | $411.85 million | 2.52 | -$86.87 million | N/A | N/A |
Titan Pharmaceuticals | $1.53 million | 9.36 | -$8.78 million | N/A | N/A |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
瓦尔尼瓦 | 4.1185亿美元 | 2.52 | -8,687万元 | 不适用 | 不适用 |
泰坦制药 | 153万美元 | 9.36 | -878万元 | 不适用 | 不适用 |
Titan Pharmaceuticals has lower revenue, but higher earnings than Valneva.
泰坦制药的营收低于Valneva,但盈利高于Valneva。
Institutional & Insider Ownership
机构与内部人持股
Profitability
盈利能力
This table compares Valneva and Titan Pharmaceuticals' net margins, return on equity and return on assets.
此表比较了Valneva和Titan制药公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Valneva | N/A | N/A | N/A |
Titan Pharmaceuticals | -1,779.72% | -183.12% | -123.74% |
净利润率 | 股本回报率 | 资产回报率 | |
瓦尔尼瓦 | 不适用 | 不适用 | 不适用 |
泰坦制药 | -1,779.72% | -183.12% | -123.74% |
Analyst Ratings
分析师评级
This is a summary of recent ratings and recommmendations for Valneva and Titan Pharmaceuticals, as provided by MarketBeat.
这是MarketBeat提供的Valneva和Titan PharmPharmticals最近的评级和推荐摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Valneva | 0 | 2 | 1 | 0 | 2.33 |
Titan Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
瓦尔尼瓦 | 0 | 2 | 1 | 0 | 2.33 |
泰坦制药 | 0 | 1 | 0 | 0 | 2.00 |
Valneva currently has a consensus price target of $25.00, indicating a potential upside of 66.89%. Given Valneva's stronger consensus rating and higher probable upside, research analysts clearly believe Valneva is more favorable than Titan Pharmaceuticals.
Valneva目前的共识目标价为25.00美元,表明潜在上行空间为66.89%。鉴于Valneva的更高共识评级和更高的可能上行空间,研究分析师显然认为Valneva比泰坦制药更有利。
Volatility & Risk
波动性与风险
Valneva has a beta of 2.84, meaning that its share price is 184% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
Valneva的贝塔系数为2.84,这意味着其股价的波动性比标准普尔500指数高出184%。相比之下,泰坦制药的贝塔系数为1.02,这意味着其股价的波动性比标准普尔500指数高出2%。
Summary
摘要
Valneva beats Titan Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
在两只股票比较的12个因素中,Valneva有9个胜过泰坦制药。
About Valneva
关于瓦尔尼瓦
(Get Rating)
(获取评级)
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
Valneva SE是一家专业疫苗公司,专注于针对未得到满足需求的传染病的预防性疫苗的开发和商业化。该公司面向旅行者的商业疫苗包括IXIARO,一种以Vero细胞培养为基础的灭活日本脑炎疫苗,用于主动免疫日本脑炎;杜考拉,一种口服疫苗,用于预防霍乱弧菌和/或产生产肠毒素大肠杆菌的不耐热毒素引起的腹泻;以及VLA2001,一种针对SARS-CoV-2的候选疫苗。该公司还开发了VLA15和VLA1553。VLA15是一种候选疫苗,已经完成了针对疏螺旋体的第二阶段临床试验;VLA1553是一种候选疫苗,正在进行针对基孔肯雅病毒的第三阶段临床试验。它的产品销往美国、加拿大、德国、奥地利、北欧、英国、其他欧洲国家和国际市场。Valneva SE与辉瑞公司合作共同开发莱姆病疫苗并将其商业化,并与布坦坦研究所合作开发、制造和营销单针基孔肯雅病疫苗。该公司成立于1998年,总部设在法国圣赫尔布赖恩。
About Titan Pharmaceuticals
关于泰坦制药公司
(Get Rating)
(获取评级)
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.
泰坦制药公司利用其长期、持续的药物输送平台ProNeura,致力于开发治疗慢性疾病的疗法。它的主要产品是普罗布芬,一种用于阿片成瘾维持治疗的丁丙诺啡植入剂。该公司由Louis R.Bucalo于1992年2月7日创立,总部设在加利福尼亚州旧金山南部。
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
接受Valneva Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Valneva和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧